Below is a list of Mallinckrodt Public Limited Company (NYSE:MNK) latest ratings and price target changes. Nationwide Fund Advsr has 0.01% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 47,405 shares. Ameriprise Financial Inc. raised its holdings in Mallinckrodt by 117.3% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,176 shares of the company's stock worth $530,000 after purchasing an additional 6,795 shares during the last quarter. Profund Advisors LLC now owns 6,399 shares of the company's stock valued at $285,000 after buying an additional 220 shares during the last quarter. LSV Asset Management raised its holdings in Mallinckrodt by 24.4% in the 2nd quarter. The number of shares now owned by investors are 96.36 mln. Institutional investors own 97.40% of the company's stock. State Street Corporation stated it has 0.02% in Mallinckrodt Public Limited Company (NYSE:MNK). 2,859,200 shares of the company's stock traded hands, compared to its average volume of 2,584,930. At the same time as, it has debt to equity ratio of 1.14 and similar long term debt to equity ratio was 1.08. ATR is an exponential moving average (consist of 14 trading days) of the True Ranges that is explaining range of a day's trading is high-low. The stock has a market capitalization of $2,086.31, a P/E ratio of 2.96, a P/E/G ratio of 0.40 and a beta of 1.30.
Mallinckrodt (NYSE:MNK) last posted its quarterly earnings results on Tuesday, November 7th. The company reported the earnings of $1.97/Share in the last quarter where the estimated EPS by analysts was $1.81/share. Mallinckrodt PLC had a net margin of 7.75% and a return on equity of 17.34%. Benjamin F Edwards And holds 0% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK) for 321 shares. During the same period in the previous year, the business earned $2.04 EPS.
In other Mallinckrodt news, General Counsel Michael-Bryant Hicks bought 7,900 shares of the firm's stock in a transaction dated Thursday, November 9th. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Oppenheimer maintained the stock with "Buy" rating in Friday, July 28 report. The stock was purchased at an average price of $21.94 per share, for a total transaction of $100,046.40. The disclosure for this purchase can be found here. Following the acquisition, the director now directly owns 19,789 shares of the company's stock, valued at approximately $434,170.66. Manchester Management Ltd Liability reported 12 shares. Stifel Nicolaus cut their price objective on shares of Mallinckrodt from $70.00 to $50.00 and set a "buy" rating for the company in a research report on Wednesday, November 8th. Korea Investment Corp owns 72,300 shares or 0.02% of their U.S. portfolio. The firm has "Buy" rating given on Friday, August 25 by Jefferies. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) has "Overweight" rating given on Wednesday, August 5 by Barclays Capital. Mizuho restated a "buy" rating and set a $73.00 price objective on shares of Mallinckrodt PLC in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the stock. Mallinckrodt presently has an average rating of "Hold" and an average target price of $48.14.
Mallinckrodt public limited company develops, makes, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The companyÂ's Specialty Brands segment markets branded pharmaceutical products for autoimmune and rare diseases, including the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and hemostasis products, and central nervous system drugs.